# Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

> **NCT02985242** · PHASE4 · TERMINATED · sponsor: **Hannover Medical School** · enrollment: 6 (actual)

## Conditions studied

- Diabetes Mellitus, Type II

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Glimepiride
- **DRUG:** Empagliflozin placebo
- **DRUG:** Glimepiride placebo

## Key facts

- **NCT ID:** NCT02985242
- **Lead sponsor:** Hannover Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-08-01
- **Final completion:** 2018-08-16
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** difficulties to recruit planned numbers of patients within reasonable time frame
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02985242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02985242, "Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02985242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*